|
1
|
Aletaha D, Neogi T, Silman AJ, et al: 2010
rheumatoid arthritis classification criteria: an American College
of Rheumatology/European League Against Rheumatism collaborative
initiative. Ann Rheum Dis. 69:1580–1588. 2010. View Article : Google Scholar
|
|
2
|
Taylor PC: Pharmacology of TNF blockade in
rheumatoid arthritis and other chronic inflammatory diseases. Curr
Opin Pharmacol. 10:308–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scott DL and Kingsley GH: Tumor necrosis
factor inhibitors for rheumatoid arthritis. N Engl J Med.
355:704–712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moreland LW, Schiff MH, Baumgartner SW, et
al: Etanercept therapy in rheumatoid arthritis. A randomized,
controlled trial Ann Intern Med. 130:478–486. 1999.PubMed/NCBI
|
|
5
|
Bathon JM, Martin RW, Fleischmann RM, et
al: A comparison of etanercept and methotrexate in patients with
early rheumatoid arthritis. N Engl J Med. 343:1586–1593. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moreland LW, Baumgartner SW, Schiff MH, et
al: Treatment of rheumatoid arthritis with a recombinant human
tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J
Med. 337:141–147. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elliott MJ, Maini RN, Feldmann M, et al:
Randomised double-blind comparison of chimeric monoclonal antibody
to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid
arthritis. Lancet. 344:1105–1110. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van den Berg WB, Joosten LA and van de Loo
FA: TNF alpha and IL-1 beta are separate targets in chronic
arthritis. Clin Exp Rheumatol. 17:S105–S114. 1999.PubMed/NCBI
|
|
9
|
Kang KY, Lee KY, Kwok SK, et al: The
change of bone mineral density according to treatment agents in
patients with ankylosing spondylitis. Joint Bone Spine. 78:188–193.
2011. View Article : Google Scholar
|
|
10
|
Ju JH, Kang KY, Kim IJ, et al:
Visualization and localization of rheumatoid knee synovitis with
FDG-PET/CT images. Clin Rheumatol. 27(Suppl 2): S39–S41. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolfe F and Michaud K: Towards an
epidemiology of rheumatoid arthritis outcome with respect to
treatment: randomized controlled trials overestimate treatment
response and effectiveness. Rheumatology (Oxford). 44 Suppl
4:iv18–iv22. 2005. View Article : Google Scholar
|
|
12
|
National Institute for Health and Clinical
Excellence. Adalimumab, etanercept and infliximab for the treatment
of rheumatoid arthritis. http://www.nice.org.uk/nicemedia/live/11867/37914/37914.pdf.
Accessed June 8, 2012
|
|
13
|
Genovese MC, Bathon JM, Martin RW, et al:
Etanercept versus methotrexate in patients with early rheumatoid
arthritis: two-year radiographic and clinical outcomes. Arthritis
Rheum. 46:1443–1450. 2002.PubMed/NCBI
|
|
14
|
O’Dell JR: Treating rheumatoid arthritis
early: a window of opportunity? Arthritis Rheum. 46:283–285.
2002.PubMed/NCBI
|
|
15
|
Ju JH, Cho ML, Jhun JY, et al: Oral
administration of type-II collagen suppresses IL-17-associated
RANKL expression of CD4+ T cells in collagen-induced
arthritis. Immunol Lett. 117:16–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamaguchi N, Ohshima S, Umeshita-Sasai M,
et al: Synergistic effect on the attenuation of collagen induced
arthritis in tumor necrosis factor receptor I (TNFRI) and
interleukin 6 double knockout mice. J Rheumatol. 30:22–27.
2003.PubMed/NCBI
|
|
17
|
Kobayashi K, Takahashi N, Jimi E, et al:
Tumor necrosis factor alpha stimulates osteoclast differentiation
by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp
Med. 191:275–286. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu H, Lacey DL, Dunstan CR, et al: Tumor
necrosis factor receptor family member RANK mediates osteoclast
differentiation and activation induced by osteoprotegerin ligand.
Proc Natl Acad Sci USA. 96:3540–3545. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lacey DL, Timms E, Tan HL, et al:
Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reagan-Shaw S, Nihal M and Ahmad N: Dose
translation from animal to human studies revisited. FASEB J.
22:659–661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Finckh A, Simard JF, Gabay C and Guerne
PA; SCQM physicians. Evidence for differential acquired drug
resistance to anti-tumour necrosis factor agents in rheumatoid
arthritis. Ann Rheum Dis. 65:746–752. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haraoui B, Cameron L, Ouellet M and White
B: Anti-infliximab antibodies in patients with rheumatoid arthritis
who require higher doses of infliximab to achieve or maintain a
clinical response. J Rheumatol. 33:31–36. 2006.PubMed/NCBI
|
|
24
|
Elkayam O, Burke M, Vardinon N, et al:
Autoantibodies profile of rheumatoid arthritis patients during
treatment with infliximab. Autoimmunity. 38:155–160. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Atzeni F, Doria A, Ghirardello A, et al:
Organ-specific autoantibodies in patients with rheumatoid arthritis
treated with adalimumab: a prospective long-term follow-up.
Autoimmunity. 41:87–91. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dore RK, Mathews S, Schechtman J, et al:
The immunogenicity, safety, and efficacy of etanercept liquid
administered once weekly in patients with rheumatoid arthritis.
Clin Exp Rheumatol. 25:40–46. 2007.PubMed/NCBI
|
|
27
|
Keystone EC, Schiff MH, Kremer JM, et al:
Once-weekly administration of 50 mg etanercept in patients with
active rheumatoid arthritis: results of a multicenter, randomized,
double-blind, placebo-controlled trial. Arthritis Rheum.
50:353–363. 2004. View Article : Google Scholar
|
|
28
|
Emi Aikawa N, de Carvalho JF, Artur
Almeida Silva C and Bonfá E: Immunogenicity of anti-TNF-alpha
agents in autoimmune diseases. Clin Rev Allergy Immunol. 38:82–89.
2010.PubMed/NCBI
|
